Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy. Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).

Trial Details

NCT ID
NCT06268665
Phase
PHASE2
Sponsor
University of California, Davis
Status
RECRUITING
Cancer Type
Breast Cancer
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944

Key Eligibility Criteria

  • Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria.
  • Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment.
  • Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed.
  • Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →